Literature DB >> 30067509

Chemotherapeutic resistance: a nano-mechanical point of view.

Collins Otieno Nyongesa1, Soyeun Park2.   

Abstract

Chemotherapeutic resistance is one of the main obstacles for cancer remission. To understand how cancer cells acquire chemotherapeutic resistance, biochemical studies focusing on drug target alteration, altered cell proliferation, and reduced susceptibility to apoptosis were performed. Advances in nano-mechanobiology showed that the enhanced mechanical deformability of cancer cells accompanied by cytoskeletal alteration is a decisive factor for cancer development. Furthermore, atomic force microscopy (AFM)-based nano-mechanical studies showed that chemotherapeutic treatments reinforced the mechanical stiffness of drug-sensitive cancer cells. However, drug-resistant cancer cells did not show such mechanical responses following chemotherapeutic treatments. Interestingly, drug-resistant cancer cells are mechanically heterogeneous, with a subpopulation of resistant cells showing higher stiffness than their drug-sensitive counterparts. The signaling pathways involving Rho, vinculin, and myosin II were found to be responsible for these mechanical alterations in drug-resistant cancer cells. In the present review, we highlight the mechanical aspects of chemotherapeutic resistance, and suggest how mechanical studies can contribute to unravelling the multifaceted nature of chemotherapeutic resistance.

Entities:  

Keywords:  Rho-GTPase; actin; atomic force microscopy; cell elasticity; chemotherapy resistance; cytoskeletal reorganization; tumor heterogeneity

Mesh:

Substances:

Year:  2018        PMID: 30067509     DOI: 10.1515/hsz-2018-0274

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  3 in total

Review 1.  Nano-scientific Application of Atomic Force Microscopy in Pathology: from Molecules to Tissues.

Authors:  Tony Mutiso Kiio; Soyeun Park
Journal:  Int J Med Sci       Date:  2020-03-15       Impact factor: 3.738

2.  ASIC1a stimulates the resistance of human hepatocellular carcinoma by promoting EMT via the AKT/GSK3β/Snail pathway driven by TGFβ/Smad signals.

Authors:  Yinci Zhang; Niandie Cao; Jiafeng Gao; Jiaojiao Liang; Yong Liang; Yinghai Xie; Shuping Zhou; Xiaolong Tang
Journal:  J Cell Mol Med       Date:  2022-04-14       Impact factor: 5.295

3.  Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients.

Authors:  Ciara Tierney; Despina Bazou; Muntasir M Majumder; Pekka Anttila; Raija Silvennoinen; Caroline A Heckman; Paul Dowling; Peter O'Gorman
Journal:  Sci Rep       Date:  2021-06-18       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.